http://rdf.ncbi.nlm.nih.gov/pubchem/reference/5401405

Outgoing Links

Predicate Object
contentType Journal Article
endingPage 2015
issn 2218-6751
2226-4477
issueIdentifier 5
pageRange 2008-2015
publicationName Translational Lung Cancer Research
startingPage 2008
bibliographicCitation Zhou Q, Chen M, Wu G, Chang JH, Jiang O, Cui JW, Han G, Lin Q, Fang J, Chen GY, Wu YL. GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008–15. PMID: 33209620; PMCID: PMC7653154.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_445c654b648495d3b87dbcd7fd58361d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7d48aa9abac264cd0690846a95f59424
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b2f7f7c025458bdb9c26dac735a29f1b
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fab902cd1e6023990fb05cd7de9d519d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1448cd99608532722f61ee4b65ba1be3
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_811c9056bfb05823d4fc4c713a814f93
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5245aa37a14f90bc5327060a92368a72
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fa07443c0d44c81b56dd18b8822be198
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_65eb895650a5e3917d2af50c9aa55958
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_75b1c469d06744eb3d1fbc362bcf3ee5
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0112e935bad89a8e23dd50a62aed0818
date 202010
identifier https://doi.org/10.21037/tlcr-20-608
https://pubmed.ncbi.nlm.nih.gov/PMC7653154
https://pubmed.ncbi.nlm.nih.gov/33209620
isPartOf https://portal.issn.org/resource/ISSN/2218-6751
https://portal.issn.org/resource/ISSN/2226-4477
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/43494
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
title GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/ unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23939
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_9d10ac455aeac1c1b4775b330405eeec

Showing number of triples: 1 to 35 of 35.